固形腫瘍を有する参加者を対象としたJNJ-1761981の研究
固形腫瘍患者を対象とした持続放出型化学療法薬JNJ-1761981 ERの腫瘍内投与に関する第I相試験
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic Rochester
-
-
New York
-
The Bronx、New York、アメリカ、10467
- 募集
- Montefiore Medical Center
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system [CNS]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines
- Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network [NCCN] guidelines) and whose disease has progressed after standard therapy
- Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1
- Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but cannot receive cetrelimab): Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
- A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months (for women) and 11 months (for men) after the last dose of JNJ-1761981 or 5 months after the last dose of cetrelimab or other anti-PD(L)1 treatment, whichever is later
Exclusion criteria:
- Active symptomatic disease involvement of the central nervous system
- Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any study endpoints of safety or the antitumor activity of the study treatment(s)
- Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
- Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients
- Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Part 1: Dose Escalation
Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose. |
JNJ-1761981 will be administered intratumorally. |
|
実験的:Part 2: Dose Expansion
Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician. |
JNJ-1761981 will be administered intratumorally. Cetrelimab will be administered intravenously.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Number of Participants with Adverse Events (AE) by Severity
時間枠:Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
時間枠:Up to 28 days
|
High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT. |
Up to 28 days
|
|
Part 1: Number of Participants with AEs by Severity Related to Delivery Device and/or Procedure
時間枠:Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants who Received Planned Total Dose per Level
時間枠:Up to approximately 28 days
|
Number of participants who received planned total dose per level will be reported. |
Up to approximately 28 days
|
|
Part 2: Administered Tumor Response Rate
時間枠:Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve complete response (CR) or partial response (PR). |
Up to approximately 2 years 10 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Parts 1 and 2: Plasma Concentration of Free and Total Platinum
時間枠:Up to approximately 2 years 10 months
|
Plasma concentration of free and total platinum will be assessed. |
Up to approximately 2 years 10 months
|
|
Part 1: Administered Tumor Response Rate
時間枠:Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve CR or PR. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Administered Tumor Duration of Response
時間枠:Up to approximately 2 years 10 months
|
Administered tumor duration of response will be calculated among JNJ-1761981 administered lesions that responded from the date of initial documentation of lesion response to the date of first documented evidence of progression or start of subsequent anticancer treatment or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
時間枠:Up to approximately 2 years 10 months
|
ORR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
時間枠:Up to approximately 2 years 10 months
|
DCR is defined as the percentage of participants who have achieved CR, PR, and stable disease for at least 4 weeks after study treatment was administered. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Duration of Response (DOR)
時間枠:Up to approximately 2 years 10 months
|
DOR will be calculated among responders from the date of initial documentation of a response (first CR/PR) to the date of first documented evidence of progression according to RECIST v.1.1, or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with Adverse Events (AE) by Severity
時間枠:Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the NCI-CTCAE v 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with AE by Severity Related to Delivery Device and/or Procedure
時間枠:Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants who Received Planned Intratumoral Volumetric Dose
時間枠:Up to approximately 2 years 10 months
|
Number of participants who received the planned intratumoral volumetric dose will be reported. |
Up to approximately 2 years 10 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Johnson & Johnson Enterprise Innovation, Inc Clinical Trial、Johnson & Johnson Enterprise Innovation Inc.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 1761981STM1001
- 1761981STM1001 (その他の識別子:Janssen Research & Development, LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。